4418-57-9

Usage

Uses

Used in Pharmaceutical Industry:
5-ETHYL-4-METHYL-4H-[1,2,4]TRIAZOLE-3-THIOL is used as a pharmaceutical compound for its potential antimicrobial, antiviral, and anticancer properties. Its unique structure allows it to interact with biological targets, making it a candidate for the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, 5-ETHYL-4-METHYL-4H-[1,2,4]TRIAZOLE-3-THIOL is used as a bioactive molecule for its potential pesticidal and fungicidal properties. Its ability to combat various pathogens can contribute to the development of more effective and environmentally friendly agrochemicals.
Used in Materials Science:
5-ETHYL-4-METHYL-4H-[1,2,4]TRIAZOLE-3-THIOL is utilized in materials science for its potential applications in the development of new materials with unique properties. Its chemical structure can be manipulated to create materials with specific characteristics, such as improved stability, reactivity, or conductivity.
Further research and testing are necessary to fully understand and unlock the potential of 5-ETHYL-4-METHYL-4H-[1,2,4]TRIAZOLE-3-THIOL in these industries and explore additional applications.

InChI:InChI=1/C5H9N3S/c1-3-4-6-7-5(9)8(4)2/h3H2,1-2H3,(H,7,9)

Relevant academic research and scientific papers

COMPOUNDS FOR MODULATING AQUAPORINS

The invention relates to compounds of formula (I) pharmaceutical compositions thereof and methods for modulating aquaporin 9.

4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4- piperzinylpyrimidine compounds have the general formula (I), wherein Ar, X, A, R1 and R 1a are as defined in the claims.

TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR

The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R1a is hydrogen or C1-C4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.